Stay updated with breaking news from Pithampur Facility. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
According to a CNBC-TV18, the warning letter has underlined data integrity issues at Cipla embedded with product complaints and microbial contamination
According to an exchange filing, the drug manufacturer was given a detailed breakdown of the lapses in methods followed at the facility by the USFDA. "This warning letter summarizes contraventions regarding methods or controls followed at the facility which do not conform to the prescribed cGMP regulations and contains directional guidance for necessary corrections," the filing said.
The site has been successfully inspected by a host of regulatory agencies including FDA (US), MHRA (UK), MPA (Sweden), TGA (Australia), FIMEA (Finland) and ANVISA (Brazil).